An agonist of liver X receptor slows valvular disease in a hypercholesterolemia mouse model

Journal of Heart Valve Disease

Volumn 19, Issue 5, 2010, Pages 653-664

  Wang, Haimei ^a   Goland, Sorel ^a   Burton, Kevin ^a   Czer, Lawrence S C ^a   Schwarz, Ernst R ^a   Trento, Alfredo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; OXIDIZED LOW DENSITY LIPOPROTEIN; T 1317; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIFICATION; CELL ADHESION; CHOLESTEROL TRANSPORT; ENDOTHELIUM CELL; FEMALE; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPID STORAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VALVULAR HEART DISEASE;

ANIMALS; AORTIC VALVE; APOLIPOPROTEINS E; CALCIUM; CELL ADHESION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; HYDROCARBONS, FLUORINATED; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPOPROTEINS, LDL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORPHAN NUCLEAR RECEPTORS; SULFONAMIDES; SWINE;

EID: 78149249394     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Magilligan DJ, Jr., Lewis JW, Jr., Tilley B, Peterson E. The porcine bioprosthetic valve. Twelve years later. J Thorac Cardiovasc Surg 1985;89:499-507
2. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: Final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000;36:1152-1158
3. Farivar RS, Cohn LH. Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation. J Thorac Cardiovasc Surg 2003;126:969-975
4. Pohle K, Maffert R, Ropers D, et al. Progression of aortic valve calcification: Association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001;104:1927-1932
5. Demer LL. Cholesterol in vascular and valvular calcification. Circulation 2001;104:1881-1883
6. Helske S, Kupari M, Lindstedt KA, Kovanen PT. Aortic valve stenosis: An active atheroinflammatory process. Curr Opin Lipidol 2007;18:483-491
7. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005;112:I229-I1234
8. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-561
9. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-2397
10. Rosenhek R. Statins for aortic stenosis. N Engl J Med 2005;352:2441-2443
11. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-1356
12. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the aortic stenosis progression observation: Measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010,121:306-314
13. Rajamannan NM. Mechanisms of aortic valve calcification. The LDL-density-radius theory: A translation from cell signaling to physiology. Am J Physiol Heart Circ Physiol;2009:H5-H15
14. Fontaine C, Rigamonti E, Nohara A, et al. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ Res 2007;101:40-49
15. Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000;14:2831-2838
16. Wong J, Quinn CM, Brown AJ. Statins inhibit synthesis of an oxysterol ligand for the liver X receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol 2004;24:2365-2371
17. Terasaka N, Hiroshima A, Koieyama T, et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett 2003;536:6-11
18. Butcher JT, Nerem RM. Valvular endothelial cells and the mechanoregulation of valvular pathology. Philos Trans R Soc Lond B Biol Sci 2007;362:1445-1457
19. Fox E, Harkins D, Taylor H, et al. Epidemiology of mitral annular calcification and its predictive value for coronary events in African Americans: The Jackson Cohort of the Atherosclerotic Risk in Communities Study. Am Heart J 2004;148:979-984
20. Fox ER, Wilson RS, Penman AD, et al. Epidemiology of pure valvular regurgitation in the large middle-aged African American cohort of the Atherosclerosis Risk in Communities study. Am Heart J 2007;154:1229-1234
21. Thanassoulis G, Massaro JM, Cury R, et al. Associations of long-term and early adult atherosclerosis risk factors with aortic and mitral valve calcium. J Am Coll Cardiol; 2010;55:2491-2498
22. Schoen FJ. Pathologic considerations in replacement heart valves and other cardiovascular prosthetic devices. Monogr Pathol 1995;37:194-222
23. Levy RJ, Schoen FJ, Levy JT, Nelson AC, Howard SL, Oshry LJ. Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats. Am J Pathol 1983;113:143-155
24. Drolet MC, Roussel E, Deshaies Y, Couet J, Arsenault M. A high fat/high carbohydrate diet induces aortic valve disease in C57BL/6J mice. J Am Coll Cardiol 2006;47:850-855
25. Miller JD, Chu Y, Brooks RM, Richenbacher WE, Pena-Silva R, Heistad DD. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 2008;52:843-850
26. Shao JS, Cheng SL, Charlton-Kachigian N, Loewy AP, Towler DA. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 2003;278:50195-50202
27. Yacoub MH, Cohn LH. Novel approaches to cardiac valve repair: From structure to function: Part I. Circulation 2004;109:942-950
28. Antonini-Canterin F, Zuppiroli A, Popescu BA, et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol 2003;92:1479-1482
29. Rosenhek R, Baumgartner H. Aortic sclerosis, aortic stenosis and lipid-lowering therapy. Expert Rev Cardiovasc Ther 2008;6:385-390
30. Rajamannan NM. Calcific aortic stenosis: Lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol 2009;29:162-168
31. Benton JA, Kern HB, Leinwand LA, Mariner PD, Anseth KS. Statins block calcific nodule formation of valvular interstitial cells by inhibiting alpha-smooth muscle actin expression. Arterioscler Thromb Vasc Biol 2009;29:1950-1957
32. Argmann CA, Edwards JY, Sawyez CG, et al. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: A role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem 2005;280:22212-22221
33. Aikawa E, Nahrendorf M, Sosnovik D, et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 2007;115:377-386
34. Farzaneh-Far A, Proudfoot D, Shanahan C, Weissberg PL. Vascular and valvar calcification: Recent advances. Heart 2001;85:13-17
35. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997;17:680-687
36. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126
37. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002;99:7604-7609
38. Laffitte BA, Repa JJ, Joseph SB, et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 2001;98:507-512
39. Levin N, Bischoff ED, Daige CL, et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol 2005;25:135-142
40. Pitsilos S, Hunt J, Mohler ER, et al. Platelet factor 4 localization in carotid atherosclerotic plaques: Correlation with clinical parameters. Thromb Haemost 2003;90:1112-1120
41. Yu G, Rux AH, Ma P, Bdeir K, Sachais BS. Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner. Blood 2005;105:3545-3551
42. Kasper B, Brandt E, Ernst M, Petersen F. Neutrophil adhesion to endothelial cells induced by platelet factor 4 requires sequential activation of Ras, Syk, and JNK MAP kinases. Blood 2006;107:1768-1775
43. -/- mice. Thromb Haemost 2007;98:1108-1113
44. Li D, Chen K, Sinha N, et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 2005;65:907-912
45. Ljungberg A, Linden D, Ameen C, Bergstrom G, Oscarsson J. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism. Growth Horm IGF Res 2007;17:154-164
46. Venkateswaran A, Laffitte BA, Joseph SB, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 2000;97:12097-12102
47. Venkateswaran A, Repa JJ, Lobaccaro JM, Bronson A, Mangelsdorf DJ, Edwards PA. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem 2000;275:14700-14707
48. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000;289:1524-1529
49. Argmann CA, Cock TA, Auwerx J. Peroxisome proliferator-activated receptor gamma: The more the merrier? Eur J Clin Invest 2005;35:82-92
50. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003;9:213-219
51. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005;96:612-616